Defunct Company
Total Trials
10
As Lead Sponsor
8
As Collaborator
2
Total Enrollment
812
NCT05213637
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
Phase: Phase 2
Role: Collaborator
Start: Apr 25, 2018
Completion: Apr 30, 2023
NCT03748836
Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 29, 2019
Completion: Nov 18, 2019
NCT03757065
Cell Surface Marker Expression in Autoimmune Diseases
Phase: N/A
Start: Jun 12, 2019
Completion: Oct 25, 2019
NCT04227938
ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD
Start: May 11, 2020
Completion: May 21, 2020
NCT04186637
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
Start: Jun 2, 2020
Completion: Feb 28, 2023
NCT04920383
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Start: Jun 22, 2021
NCT05034484
A Study of ALPN-303 in Adult Healthy Volunteers
Start: Nov 15, 2021
Completion: Feb 27, 2023
NCT05732402
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Phase: Phase 1/2
Start: Mar 15, 2023
Completion: Mar 2, 2028
NCT05757570
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
Start: Jul 3, 2023
Completion: Jul 31, 2026